J. Costentin, Pharmacothérapie pratique à l'officine : l'essentiel, 2004.

S. Stahl, Psychopharmacologie essentielle : Bases neuroscientifiques et applications pratiques, 2010.

T. Amato and M. Saoud, La schizophrénie de l'adulte : Des causes aux traitements, 2006.

A. P. Associati, DSM-IV-TR Manuel diagnostique et statistique des troubles mentaux : Texte révisié, 2003.

T. A. Ban, Fifty years chlorpromazine: a historical perspective, Neuropsychiatr. Dis. Treat, vol.3, pp.495-500, 2007.

D. , J. Deniker, P. Harl, and J. M. , Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)], Ann. Méd.-Psychol, vol.110, pp.112-117, 1952.

A. Carlsson and M. Lindqvist, Effect of Chlorpromazine or Haloperidol on Formation of 3-Methoxytyramine and Normetanephrine in Mouse Brain, Acta Pharmacologica et Toxicologica, vol.8, issue.no. 7, pp.140-144, 1963.
DOI : 10.1111/j.1600-0773.1963.tb01730.x

J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, Clozapine for the Treatment-Resistant Schizophrenic, Archives of General Psychiatry, vol.45, issue.9, pp.789-796, 1988.
DOI : 10.1001/archpsyc.1988.01800330013001

L. , P. A. Revol, and L. , Psychopharmacological and clinical classification of different neuroleptic drugs. General therapeutic indications in psychoses, Presse Médicale, pp.1509-1511, 1960.

J. Bobon, A. Pinchard, J. Collard, and D. P. Bobon, Clinical classification of neuroleptics, with special reference to their antimanic, antiautistic, and ataraxic properties, Comprehensive Psychiatry, vol.13, issue.2, pp.123-131, 1972.
DOI : 10.1016/0010-440X(72)90017-X

M. John and D. , Dose equivalence of the anti-psychotic drugs, J. Psychiatr. Res, vol.11, pp.65-69, 1974.

I. Gasman and J. Allilaire, Psychiatrie de l'enfant, de l'adolescent et de l'adulte, 2009.

A. Sharma, V. Madaan, and F. Petty, Propranolol Treatment for Neuroleptic-Induced Akathisia, The Primary Care Companion to The Journal of Clinical Psychiatry, vol.07, issue.04, pp.202-203, 2005.
DOI : 10.4088/PCC.v07n0412b

C. H. Miller and W. W. Fleischhacker, Managing Antipsychotic-Induced Acute and Chronic Akathisia, Drug Safety, vol.28, issue.6, pp.73-81, 2000.
DOI : 10.2165/00002018-200022010-00006

/. Hcp, . Moa, and . Default, FMPMC-PS -Pharmacologie -DCEM1, XENAZINE® (tetrabenazine) Move of Action

R. A. Dickson and W. M. Glazer, Neuroleptic-induced hyperprolactinemia, Schizophrenia Research, vol.35, pp.75-86, 1999.
DOI : 10.1016/S0920-9964(98)00159-5

. Rennes20091217095109fcarrecoursthermoregulation1 and . Pdf, at <http://facmed.univ- rennes1.fr

D. Meulendijks, C. K. Mannesse, P. A. Jansen, R. J. Van-marum, and T. C. Egberts, Antipsychotic-Induced Hyponatraemia, Drug Safety, vol.131, issue.10, pp.101-114, 2010.
DOI : 10.2165/11319070-000000000-00000

L. Praticien, . Une, and . Galactorrhée, at <http://www.gyneweb.fr/Sources/gyngene/gynendoc/galact.html> 41. Nos derniers articles > La thyroide : signes et causes de mauvais fonctionnements

R. B. Khalil and S. Richa, Thyroid Adverse Effects of Psychotropic Drugs, Clinical Neuropharmacology, vol.34, issue.6, pp.248-255, 2011.
DOI : 10.1097/WNF.0b013e31823429a7

J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington, Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis, BMJ, vol.321, issue.7273, pp.1371-1376, 2000.
DOI : 10.1136/bmj.321.7273.1371

D. Vidal and . Vidal, French version of American Physician's Desk Reference (PDR)) (Dictionnaire Vidal (French & European Publishing)) (French Edition), 2011.

S. Kapur, R. B. Zipursky, and G. Remington, Clinical and theoretical implications of 5- HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia, Am. J. Psychiatry, vol.156, pp.286-293, 1999.

T. Barnes, Antipsychotic Drugs and Their Side-Effects, 1993.

J. Hoey and E. Wooltorton, Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials, CMAJ Can. Med. Assoc. J, vol.170, p.1395, 2004.

A. F. Lehman, Practice guideline for the treatment of patients with schizophrenia, second edition, Am. J. Psychiatry, vol.161, pp.1-56, 2004.

C. Chiu, C. Chen, and B. Chen, The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.34, issue.6, 2010.
DOI : 10.1016/j.pnpbp.2010.04.003

J. W. Newcomer, Metabolic syndrome and mental illness, 2007.

M. Hasnain, S. K. Fredrickson, W. V. Vieweg, and A. K. Pandurangi, Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics, Current Diabetes Reports, vol.58, issue.Suppl 1, pp.209-216, 2010.
DOI : 10.1007/s11892-010-0112-8

V. Eapen and G. John, Weight Gain and Metabolic Syndrome Among Young Patients on Antipsychotic Medication: What do we Know and Where do we go?, Australasian Psychiatry, vol.66, issue.3, 2011.
DOI : 10.3109/10398562.2010.539609

D. Hert, M. Dobbelaere, M. Sheridan, E. M. Cohen, D. Correll et al., Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice, European Psychiatry, vol.26, issue.3, pp.144-158, 2011.
DOI : 10.1016/j.eurpsy.2010.09.011

J. U. Ohaeri and A. Akanji, Metabolic Syndrome in Severe Mental Disorders, Metabolic Syndrome and Related Disorders, vol.9, issue.2, pp.91-98, 2011.
DOI : 10.1089/met.2010.0053

J. L. Després, obé sité abdominale, une maladie mé tabolique, 2007.

. Obepi-roche, enquête épidémiologique de référence sur l'évolution de l'obésité et du surpoids en France

H. Autorité and D. Santé, Surpoids et obésité de l'adulte : prise en charge médicale de premier recours. at <http://www.has-sante.fr/portail/jcms/c_964938/fr/surpoids-et- obesite-de-l-adulte-prise-en-charge-medicale-de-premier-recours>

R. Keefe, R. Bilder, and S. Davis, Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial, Archives of General Psychiatry, vol.64, issue.6, pp.633-647, 2007.
DOI : 10.1001/archpsyc.64.6.633

D. E. Casey, Metabolic issues and cardiovascular disease in patients with psychiatric disorders, The American Journal of Medicine Supplements, vol.118, issue.2, pp.15-22, 2005.
DOI : 10.1016/j.amjmed.2005.01.046

S. Mukherjee, P. Decina, V. Bocola, F. Saraceni, and P. L. Scapicchio, Diabetes mellitus in schizophrenic patients, Comprehensive Psychiatry, vol.37, issue.1, pp.68-73, 1996.
DOI : 10.1016/S0010-440X(96)90054-1

S. Mukherjee, D. B. Schnur, and R. Reddy, FAMILY HISTORY OF TYPE 2 DIABETES IN SCHIZOPHRENIC PATIENTS, The Lancet, vol.333, issue.8636, p.495, 1989.
DOI : 10.1016/S0140-6736(89)91392-5

F. Bellivier and . Schizophrenia, Schizophrenia, antipsychotics and diabetes: Genetic aspects, European Psychiatry, vol.20, pp.335-339, 2005.
DOI : 10.1016/S0924-9338(05)80187-7

T. G. Dinan, Stress and the genesis of diabetes mellitus in schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.72-75, 2004.
DOI : 10.1192/bjp.184.47.s72

J. L. Megna, T. L. Schwartz, U. A. Siddiqui, and M. Herrera-rojas, Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Ann. Clin. Psychiatry Off. J. Am. Acad. Clin. Psychiatr, vol.23, pp.131-140, 2011.

S. Chabroux, E. Haffen, and A. Penfornis, Diab??te et antipsychotiques de seconde g??n??ration, Annales d'Endocrinologie, vol.70, issue.4, pp.202-210, 2009.
DOI : 10.1016/j.ando.2009.07.003

C. B. Nemeroff, Dosing the antipsychotic medication olanzapine, J. Clin. Psychiatry, vol.58, pp.45-49, 1997.

J. A. Lieberman, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1223, 2005.
DOI : 10.1056/NEJMoa051688

D. B. Allison, Antipsychotic-induced weight gain: a comprehensive research synthesis, Am. J. Psychiatry, vol.156, pp.1686-1696, 1999.

S. Leucht, S. Wagenpfeil, J. Hamann, and W. Kissling, Amisulpride is an ?atypical? antipsychotic associated with low weight gain, Psychopharmacology, vol.173, issue.1-2, pp.112-115, 2004.
DOI : 10.1007/s00213-003-1721-6

M. F. Juruena, E. P. De-sena, and I. De-oliveira, Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthc, Patient Saf, vol.2, pp.205-211, 2010.

H. Nasrallah, A review of the effect of atypical antipsychotics on weight, Psychoneuroendocrinology, vol.28, pp.83-96, 2003.
DOI : 10.1016/S0306-4530(02)00114-2

D. E. Casey, Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia, J. Clin. Psychiatry, vol.65, pp.4-18, 2004.

J. W. Newcomer, Second-Generation (Atypical) Antipsychotics and Metabolic Effects, CNS Drugs, vol.161, issue.4, pp.1-93, 2005.
DOI : 10.2165/00023210-200519001-00001

D. C. Henderson, Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study, American Journal of Psychiatry, vol.157, issue.6, pp.975-981, 2000.
DOI : 10.1176/appi.ajp.157.6.975

K. Melkersson and M. Dahl, Adverse Metabolic Effects Associated with Atypical Antipsychotics, Drugs, vol.286, issue.7, pp.701-723, 2004.
DOI : 10.2165/00003495-200464070-00003

D. Hert and M. , A Case Series: Evaluation of the Metabolic Safety of Aripiprazole, Schizophrenia Bulletin, vol.33, issue.3, pp.823-830, 2007.
DOI : 10.1093/schbul/sbl037

E. A. Koller, J. T. Cross, P. M. Doraiswamy, and B. S. Schneider, Risperidone-Associated Diabetes Mellitus: A Pharmacovigilance Study, Pharmacotherapy, vol.60, issue.23, pp.735-744, 2003.
DOI : 10.1016/S0304-3940(99)00712-0

E. Koller, B. Schneider, K. Bennett, and G. Dubitsky, Clozapine-associated diabetes, The American Journal of Medicine, vol.111, issue.9, pp.716-723, 2001.
DOI : 10.1016/S0002-9343(01)01000-2

E. A. Koller and P. M. Doraiswamy, Olanzapine-Associated Diabetes Mellitus, Pharmacotherapy, vol.46, issue.7, pp.841-852, 2002.
DOI : 10.4088/JCP.v61n1111b

E. A. Koller, J. Weber, P. M. Doraiswamy, and B. S. Schneider, A Survey of Reports of Quetiapine-Associated Hyperglycemia and Diabetes Mellitus, The Journal of Clinical Psychiatry, vol.65, issue.6, pp.857-863, 2004.
DOI : 10.4088/JCP.v65n0619

A. E. Kostako?lu, K. M. Yazici, T. Erba?, and N. Güvener, Ketoacidosis as a side-effect of clozapine: a case report, Acta Psychiatrica Scandinavica, vol.151, issue.3, pp.217-218, 1996.
DOI : 10.1111/j.1600-0447.1996.tb10635.x

G. A. Peterson and S. L. Byrd, Diabetic ketoacidosis from clozapine and lithium cotreatment, Am. J. Psychiatry, vol.153, pp.737-738, 1996.

A. J. Scheen, Current Management Strategies for Coexisting Diabetes Mellitus and Obesity, Drugs, vol.44, issue.12, pp.1165-1184, 2003.
DOI : 10.2165/00003495-200363120-00001

V. L. Albaugh, R. Singareddy, D. Mauger, and C. J. Lynch, A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers, PLoS ONE, vol.35, issue.8, p.22662, 2011.
DOI : 10.1371/journal.pone.0022662.s002

J. M. Meyer and C. Koro, The effects of antipsychotic therapy on serum lipids: a comprehensive review, Schizophrenia Research, vol.70, issue.1, pp.1-17, 2004.
DOI : 10.1016/j.schres.2004.01.014

J. K. Patel, Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study, Schizophrenia Research, vol.111, issue.1-3, pp.9-16, 2009.
DOI : 10.1016/j.schres.2009.03.025

M. Hasnain, Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications, Primary Care Diabetes, vol.3, issue.1, pp.5-15, 2009.
DOI : 10.1016/j.pcd.2008.10.005

R. A. Baker, Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis, Psychopharmacol. Bull, vol.42, pp.11-31, 2009.

E. J. Duncan, S. L. Woolson, R. M. Hamer, and B. W. Dunlop, Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population, International Clinical Psychopharmacology, vol.24, issue.4, pp.204-213, 2009.
DOI : 10.1097/YIC.0b013e32832d6c18

M. T. Lambert, L. A. Copeland, N. Sampson, and S. A. Duffy, New-onset type-2 diabetes associated with atypical antipsychotic medications, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.30, issue.5, pp.919-923, 2006.
DOI : 10.1016/j.pnpbp.2006.02.007

M. D. Sikich and . Linmarie, Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset Schizophrenia and Schizo-affective Disorder: Findings From the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study, American Journal of Psychiatry, vol.165, issue.11, pp.1420-1431, 2008.
DOI : 10.1176/appi.ajp.2008.08050756

H. Mulder, The Association Between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With Schizophrenia, Journal of Clinical Psychopharmacology, vol.27, issue.4, pp.338-343, 2007.
DOI : 10.1097/JCP.0b013e3180a76dc0

C. Torrent, Weight gain in bipolar disorder: pharmacological treatment as a contributing factor, Acta Psychiatrica Scandinavica, vol.66, issue.1, pp.4-18, 2008.
DOI : 10.1034/j.1600-0447.2001.00240.x

S. Rege, Antipsychotic Induced Weight Gain in Schizophrenia: Mechanisms and Management, Australian & New Zealand Journal of Psychiatry, vol.58, issue.5, pp.369-381, 2008.
DOI : 10.1176/ajp.2006.163.12.2072

S. Buchholz, A. F. Morrow, and P. L. Coleman, Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms, Internal Medicine Journal, vol.111, issue.7, pp.602-606, 2008.
DOI : 10.1111/j.1445-5994.2008.01712.x

A. Gunes, K. I. Melkersson, M. G. Scordo, and M. Dahl, Association Between HTR2C and HTR2A Polymorphisms and Metabolic Abnormalities in Patients Treated With Olanzapine or Clozapine, Journal of Clinical Psychopharmacology, vol.29, issue.1, pp.65-68, 2009.
DOI : 10.1097/JCP.0b013e31819302c3

H. Jin, J. M. Meyer, S. Mudaliar, and D. V. Jeste, Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin, Schizophrenia Research, vol.100, issue.1-3, pp.70-85, 2008.
DOI : 10.1016/j.schres.2007.11.026

. Cottier, Effets métaboliques et endocriniens des antipsychotiques atypiques, 2003.

T. Brömel, Serum leptin levels increase rapidly after initiation of clozapine therapy, Molecular Psychiatry, vol.3, issue.1, pp.76-80, 1998.
DOI : 10.1038/sj.mp.4000352

F. M. Theisen, A prospective study of serum ghrelin levels in patients treated with clozapine, Journal of Neural Transmission, vol.50, issue.10, pp.1411-1416, 1996.
DOI : 10.1007/s00702-005-0284-6

P. Monteleone, M. Fabrazzo, A. Tortorella, L. Pia, S. Maj et al., Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.424-426, 2002.
DOI : 10.1097/00004714-200208000-00015

J. Fernø, Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation, PLoS ONE, vol.117, issue.6, p.20571, 2011.
DOI : 10.1371/journal.pone.0020571.t001

D. E. Johnson, Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets: Role of Muscarinic Antagonism in Antipsychotic-Induced Diabetes and Hyperglycemia, Diabetes, vol.54, issue.5, pp.1552-1558, 2005.
DOI : 10.2337/diabetes.54.5.1552

M. Foretz, N. Taleux, and B. Guigas, Régulation du métabolisme énergétique par l'APMK, Med. Sci, vol.22, 2006.

J. Hanonune, Le journal faxé de l'endocrinologue sur le mécanisme d'action central de la leptine, 2008.

M. Ikegami, Olanzapine-Induced Hyperglycemia: Possible Involvement of Histaminergic, Dopaminergic and Adrenergic Functions in the Central Nervous System, Neuroendocrinology, vol.98, issue.3, 2013.
DOI : 10.1159/000356119

M. Ikegami, Olanzapine induces glucose intolerance through the activation of AMPK in the mouse hypothalamus, European Journal of Pharmacology, vol.718, issue.1-3, 2013.
DOI : 10.1016/j.ejphar.2013.08.006

G. D. Lopaschuk, J. R. Ussher, and J. S. Jaswal, Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite, Pharmacological Reviews, vol.62, issue.2, pp.237-264, 2010.
DOI : 10.1124/pr.109.002428

C. From, Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

. Endocrinologie, Tome 2: Orientations diagnostiques : les spécificités de l'adolescence, 2013.

P. Mackin, D. R. Bishop, and H. M. Watkinson, A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients, BMC Psychiatry, vol.19, issue.6 Suppl, p.28, 2007.
DOI : 10.1177/0269881105058380

S. K. Praharaj, A. K. Jana, N. Goyal, and V. K. Sinha, Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis, British Journal of Clinical Pharmacology, vol.24, issue.3, pp.377-382, 2011.
DOI : 10.1111/j.1365-2125.2010.03783.x

. La-metformine-est-le-médicament, appelé aussi diabète non insulinodépendant. at <http://www.inserm.fr/espace-journalistes/le-medicament-en-premiere-ligne-dans-le- traitement-du-diabete-de-type-2-devoile-ses-secrets-de-fonctionnement> 131. ameli.fr -Convention nationale des pharmaciens titulaires d'officine